BioNTech faces its biggest post pandemic crisis
BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders. Can its ambitious cancer trials turn it from a one-hit wonder into a biotech giant?
schedule
14:42
visibility
70 views
Source: DW News
BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders. Can its ambitious cancer trials turn it from a one-hit wonder into a biotech giant?
The Guardian 